Last reviewed · How we verify
REZ
REZ is a monoclonal antibody that targets the CD19 protein on B cells.
REZ is a monoclonal antibody that targets the CD19 protein on B cells. Used for Relapsed or refractory diffuse large B-cell lymphoma, Relapsed or refractory follicular lymphoma, Relapsed or refractory mantle cell lymphoma.
At a glance
| Generic name | REZ |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Drug class | Monoclonal antibody |
| Target | CD19 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
By binding to CD19, REZ triggers the destruction of B cells, which are a type of immune system cell that can contribute to various diseases. This mechanism is particularly effective in treating certain types of blood cancers.
Approved indications
- Relapsed or refractory diffuse large B-cell lymphoma
- Relapsed or refractory follicular lymphoma
- Relapsed or refractory mantle cell lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) (PHASE3)
- International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 (PHASE3)
- Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children (PHASE2, PHASE3)
- ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia (PHASE4)
- TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance (NA)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- REZ CI brief — competitive landscape report
- REZ updates RSS · CI watch RSS
- Centers for Disease Control and Prevention portfolio CI